DE602006014502D1 - Pyrazolopyrimidine als zellzyklus-kinasehemmer - Google Patents

Pyrazolopyrimidine als zellzyklus-kinasehemmer

Info

Publication number
DE602006014502D1
DE602006014502D1 DE602006014502T DE602006014502T DE602006014502D1 DE 602006014502 D1 DE602006014502 D1 DE 602006014502D1 DE 602006014502 T DE602006014502 T DE 602006014502T DE 602006014502 T DE602006014502 T DE 602006014502T DE 602006014502 D1 DE602006014502 D1 DE 602006014502D1
Authority
DE
Germany
Prior art keywords
cell cycle
pyrazolopyrimidine
cycle kinase
hemmer
kinase hemmer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006014502T
Other languages
English (en)
Inventor
Eddy Jean Freyne
Jean Fernand LACRAMPE
Timothy Pietro Perera
Holte Peter Ten
Yannick Aime Ligny
Delphine Yvonne Lardeau
Tom Lavrijssen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of DE602006014502D1 publication Critical patent/DE602006014502D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE602006014502T 2005-01-14 2006-01-09 Pyrazolopyrimidine als zellzyklus-kinasehemmer Active DE602006014502D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05100215 2005-01-14
US64476605P 2005-01-18 2005-01-18
PCT/EP2006/050096 WO2006074984A1 (en) 2005-01-14 2006-01-09 Pyrazolopyrimidines as cell cycle kinase inhibitors

Publications (1)

Publication Number Publication Date
DE602006014502D1 true DE602006014502D1 (de) 2010-07-08

Family

ID=34938518

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006014502T Active DE602006014502D1 (de) 2005-01-14 2006-01-09 Pyrazolopyrimidine als zellzyklus-kinasehemmer

Country Status (9)

Country Link
US (1) US7947694B2 (de)
EP (1) EP1844048B1 (de)
JP (1) JP5190270B2 (de)
AT (1) ATE469154T1 (de)
AU (1) AU2006205850A1 (de)
CA (1) CA2594422A1 (de)
DE (1) DE602006014502D1 (de)
ES (1) ES2345997T3 (de)
WO (1) WO2006074984A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007003375A (es) * 2004-09-22 2007-05-07 Janssen Pharmaceutica Nv Inhibidores de la interaccion entre mdm2 y p53.
JP5190270B2 (ja) 2005-01-14 2013-04-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 細胞周期キナーゼ阻害剤としてのピラゾロピリミジン
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
AU2008211108A1 (en) * 2007-01-30 2008-08-07 Biogen Idec Ma Inc. 1-h-pyrazolo (3,4b) pyrimidine derivatives and their use as modulators of mitotic kinases
EP2778155A1 (de) * 2007-01-31 2014-09-17 Vertex Pharmaceuticals Incorporated 2-Aminopyridinderivate als Kinaseinhibitoren
TW200920369A (en) 2007-10-26 2009-05-16 Amira Pharmaceuticals Inc 5-lipoxygenase activating protein (flap) inhibitor
EP2285803A4 (de) 2008-05-23 2011-10-05 Amira Pharmaceuticals Inc Hemmer des 5-lipoxygenase aktivierenden proteins
DK2299821T3 (en) 2008-06-10 2016-02-15 Abbvie Inc Tricyclic compounds
AU2009274023A1 (en) 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
WO2010011756A1 (en) 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors
US8569337B2 (en) 2008-07-23 2013-10-29 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
EP2313372B1 (de) 2008-08-06 2013-04-10 Vertex Pharmaceuticals Incorporated Aminopyridine als kinaseinhibitoren
US8546431B2 (en) 2008-10-01 2013-10-01 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
WO2010129668A1 (en) 2009-05-06 2010-11-11 Vertex Pharmaceuticals Incorporated Pyrazolopyridines
RU2711869C3 (ru) 2009-12-01 2022-02-02 Эббви Инк. Имидазопирролопиразиновые производные, полезные для лечения заболеваний, вызванных аномальной активностью протеинкиназ Jak1, Jak3 или Syk
PE20130005A1 (es) 2009-12-01 2013-02-16 Abbvie Inc Compuestos triciclicos novedosos
EP2550272A1 (de) 2010-01-27 2013-01-30 Vertex Pharmaceuticals Incorporated Pyrazolopyrazinkinasehemmer
WO2011094290A1 (en) 2010-01-27 2011-08-04 Vertex Pharmaceuticals Incorporated Pyrazolopyrimidine kinase inhibitors
JP5769733B2 (ja) 2010-01-27 2015-08-26 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated ピラゾロピリジンキナーゼ阻害剤
WO2011156698A2 (en) 2010-06-11 2011-12-15 Abbott Laboratories NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS
WO2013130461A1 (en) * 2012-02-29 2013-09-06 The Scripps Research Institute Wee1 degradation inhibitors
WO2013134562A1 (en) 2012-03-09 2013-09-12 Inception 2, Inc. Triazolone compounds and uses thereof
EP2922847A1 (de) 2012-11-20 2015-09-30 Vertex Pharmaceuticals Incorporated Verbindungen als inhibitoren der indolamin-2,3-dioxygenase
KR102300675B1 (ko) 2012-12-20 2021-09-13 템페스트 테라퓨틱스, 인코포레이티드 트리아졸론 화합물 및 이의 용도
MX2016002795A (es) 2013-09-06 2016-05-26 Inception 2 Inc Compuestos de triazolona y usos de los mismos.
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
JP6770775B2 (ja) 2015-10-16 2020-10-21 アッヴィ・インコーポレイテッド (3S,4R)−3−エチル−4−(3H−イミダゾ[1,2−a]ピロロ[2,3−e]−ピラジン−8−イル)−N−(2,2,2−トリフルオロエチル)ピロリジン−1−カルボキサミドおよびそれの固体型の製造方法
CN106831780A (zh) * 2015-12-03 2017-06-13 南开大学 具有cdk4/6和hdac抑制活性的新型杂环衍生物
TW202110849A (zh) * 2019-05-27 2021-03-16 大陸商迪哲(江蘇)醫藥股份有限公司 Dna依賴性蛋白激酶抑制劑
JP2023509452A (ja) 2020-01-03 2023-03-08 バーグ エルエルシー がんを処置するためのube2kモジュレータとしての多環式アミド

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0153976A3 (de) 1983-12-08 1988-07-27 Kolbus GmbH & Co. KG Verfahren zum Prüfen von entleerten Fässern, insbesondere mit Füll- und Zapfarmaturen versehene Bierfässer, auf ihre Wiederverwendung
BR9714349A (pt) 1996-10-16 2000-11-14 Icn Pharmaceuticals L-nucleosìdeos purina, seus análogos e utilizacões dos mesmos
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
US20030187261A1 (en) 2000-01-07 2003-10-02 Libor Havlicek Purine derivatives, process for their preparation and use thereof
AU2002365211A1 (en) 2001-07-10 2003-09-02 Bristol-Myers Squibb Pharma Company 6-substituted pyrazolo (3,4-d) pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
TW200400034A (en) * 2002-05-20 2004-01-01 Bristol Myers Squibb Co Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
EP1590341B1 (de) * 2003-01-17 2009-06-17 Warner-Lambert Company LLC 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation
WO2004094426A1 (en) 2003-04-21 2004-11-04 Ustav Organické Chemie A Biochemie Akademie Ved Ceské Republiky (purin-6-yl) amino acid and production method thereof
JP5190270B2 (ja) 2005-01-14 2013-04-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 細胞周期キナーゼ阻害剤としてのピラゾロピリミジン

Also Published As

Publication number Publication date
EP1844048B1 (de) 2010-05-26
EP1844048A1 (de) 2007-10-17
JP5190270B2 (ja) 2013-04-24
ES2345997T3 (es) 2010-10-07
US20080039477A1 (en) 2008-02-14
JP2008526919A (ja) 2008-07-24
AU2006205850A1 (en) 2006-07-20
WO2006074984A1 (en) 2006-07-20
US7947694B2 (en) 2011-05-24
CA2594422A1 (en) 2006-07-20
ATE469154T1 (de) 2010-06-15

Similar Documents

Publication Publication Date Title
DE602006014502D1 (de) Pyrazolopyrimidine als zellzyklus-kinasehemmer
TW200801003A (en) Novel compounds
TW200745114A (en) Novel compounds
TW200626559A (en) Anilino-pyrimidine analogs
MX2013006101A (es) Compuestos heterociclicos nitrogenados sustituidos fusionados en posicion 6,6 y usos de los mismos.
TW200744604A (en) P38 MAP kinase inhibitors and methods for using the same
IL185275A0 (en) N-sulphonylpyrrole derivatives and pharmaceutical compositions containing the same
TW200616978A (en) Quinazolinone derivatives as parp inhibitors
SG154433A1 (en) Phthalazine derivatives as parp inhibitors
MX2009006397A (es) Derivados de imidazotiazol.
GEP20094785B (en) Pyrrolopyrazoles, potent kinase inhibitors
SG154432A1 (en) Quinazolinedione derivatives as parp inhibitors
DK2134691T3 (da) Quinolinonderivativer som parp- og tank-inhibitorer
EA200870116A1 (ru) Бициклические гетероарильные соединения
TW200740815A (en) P38 MAP kinase inhibitors and methods for using the same
SG151250A1 (en) Substituted 6-cyclohexylalkyl substituted 2-quinolinones and 2- quinoxalinones as poly(adp-ribose) polymerase inhibitors
IL177962A0 (en) Compounds and methods for treating dyslipidemia
TW200728290A (en) Chemical compounds
TW200745028A (en) Novel sulphonylpyrroles
NO20062892L (no) 7-fenylalkyl-substituert 2-kinolinoner og 2-kinoksalinoner som poly(adp-ribose)-polymeraseinhibitorer
TW200745027A (en) Novel sulphonylpyrroles
TW200745067A (en) Novel compounds
ATE533759T1 (de) Imidazolinon- und hydantoinderivate als neue inhibitoren von histondeacetylase
TW200833670A (en) Novel compounds 569
TW200740781A (en) Novel compounds

Legal Events

Date Code Title Description
8364 No opposition during term of opposition